The global antiemetics market was valued at $2,251.68 million in 2021, and is projected to reach $4,061.36 million by 2031, registering a CAGR of 6.1% from 2022 to 2031.
Emesis also known as vomiting or throwing up refers to involuntary, forceful expulsion of substances out of the stomach through mouth or sometimes through nose and medications used to stop these involuntary expulsions are known as antiemetics. Seasickness and other motion sicknesses, early pregnancy, intense pain, exposure to chemical toxins, emotional stress (fear), gallbladder disease, food poisoning and indigestion are some of the common causes associated with emesis. In addition, chemotherapy, gastroenteritis, general anesthesia, intestinal obstruction, migraine and others serious ailments may also lead to nausea and vomiting in the patient.
Rise in number of chemotherapies is one of the major driving factor for the growth of the antiemetics market. According to the American Cancer Society (ACS), 609,360 cancer deaths and 1.9 million new cases are anticipated to occur in the United States in 2022. The rate of cancer fatalities for both men and women combined has declined to 32% from its high in 1991 to 2019. The surge in adoption of various cancer therapies by the patient, including chemotherapy and radiation therapy, is mainly responsible for this decline in death rates. The use of chemotherapy and radiation therapy is expected to boost demand for antiemetic medications because these treatments are associated with adverse effects like nausea and vomiting. Thus, it is anticipated that a high prevalence of cancer cases and extensive use of chemotherapy as the treatment option will fuel the global antiemetics market during the forecast period.
Furthermore, rise in funding by governments of various countries and private organizations to initiate manufacturing units are expected to boost the market growth. Also, the government organizations of the respective countries are proving funds to carry out the research and development for the new molecules, which boost the growth of the market in that region. In addition, acquisition and partnerships by the key market players are the boosting factors for the market. These key strategies are mainly adopted by the key market players to expand their business and their product portfolio, which leads to increase in sales of the company, along with the growth of the market.
Additionally, the occurrence of gastroenteritis, often known as stomach flu, contributes to market growth. Gastroenteritis is an inflammation of the stomach and intestines that is typically brought on by viruses, bacteria, or parasites infected food or water. It produces nausea, fever, cramps, nausea, and headaches in addition to stomach discomfort and cramping. Additionally, Norovirus is a prominent source of gastroenteritis and foodborne disease outbreaks in the United States, which causes nausea and vomiting in the patients. This prevalence of Norovirus infection, demands for the antiemetics treatment medications, which is driving up sales of antiemetics in this region and boosting market growth overall.
However, less awareness about antiemetic drugs among the population hinders growth of the market. In some cases, the strength, dose and drug class of the prescribed antiemetics may lead to the severe condition in the patients, which demands for the proper knowledge regarding the medicine and its pharmacology, which can act as a restraint to the antiemetics market. On the contrary, rise in research and development activities by key market players and increase in healthcare expenditure has further encouraged many key players to enter emerging markets, thus offering lucrative opportunities for the expansion of the antiemetics market. Also, the presence of raw material in the developing regions such as Asia and LAMEA, provides lucrative opportunities for the market players to invest in this region.
The global antiemetics market is segmented on the basis of drug type, application, distribution channel, and region. By drug type, the market is categorized into antihistamines, serotonin receptor antagonists, dopamine receptor antagonists, neurokinin receptor antagonists, anticholinergics, and others. Depending on application, it is segmented into chemotherapy, post-operative surgery, pregnancy and gastroenteritis, and others. On the basis distribution channel, it is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global Antiemetics market are Abbott Laboratories, Benuvia Therapeutics Inc., Cipla, Dr. Reddy’s Laboratories Ltd, Eisai Co. Ltd, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Pfizer In. and Teva Pharmaceuticals among others.
Emesis also known as vomiting or throwing up refers to involuntary, forceful expulsion of substances out of the stomach through mouth or sometimes through nose and medications used to stop these involuntary expulsions are known as antiemetics. Seasickness and other motion sicknesses, early pregnancy, intense pain, exposure to chemical toxins, emotional stress (fear), gallbladder disease, food poisoning and indigestion are some of the common causes associated with emesis. In addition, chemotherapy, gastroenteritis, general anesthesia, intestinal obstruction, migraine and others serious ailments may also lead to nausea and vomiting in the patient.
Rise in number of chemotherapies is one of the major driving factor for the growth of the antiemetics market. According to the American Cancer Society (ACS), 609,360 cancer deaths and 1.9 million new cases are anticipated to occur in the United States in 2022. The rate of cancer fatalities for both men and women combined has declined to 32% from its high in 1991 to 2019. The surge in adoption of various cancer therapies by the patient, including chemotherapy and radiation therapy, is mainly responsible for this decline in death rates. The use of chemotherapy and radiation therapy is expected to boost demand for antiemetic medications because these treatments are associated with adverse effects like nausea and vomiting. Thus, it is anticipated that a high prevalence of cancer cases and extensive use of chemotherapy as the treatment option will fuel the global antiemetics market during the forecast period.
Furthermore, rise in funding by governments of various countries and private organizations to initiate manufacturing units are expected to boost the market growth. Also, the government organizations of the respective countries are proving funds to carry out the research and development for the new molecules, which boost the growth of the market in that region. In addition, acquisition and partnerships by the key market players are the boosting factors for the market. These key strategies are mainly adopted by the key market players to expand their business and their product portfolio, which leads to increase in sales of the company, along with the growth of the market.
Additionally, the occurrence of gastroenteritis, often known as stomach flu, contributes to market growth. Gastroenteritis is an inflammation of the stomach and intestines that is typically brought on by viruses, bacteria, or parasites infected food or water. It produces nausea, fever, cramps, nausea, and headaches in addition to stomach discomfort and cramping. Additionally, Norovirus is a prominent source of gastroenteritis and foodborne disease outbreaks in the United States, which causes nausea and vomiting in the patients. This prevalence of Norovirus infection, demands for the antiemetics treatment medications, which is driving up sales of antiemetics in this region and boosting market growth overall.
However, less awareness about antiemetic drugs among the population hinders growth of the market. In some cases, the strength, dose and drug class of the prescribed antiemetics may lead to the severe condition in the patients, which demands for the proper knowledge regarding the medicine and its pharmacology, which can act as a restraint to the antiemetics market. On the contrary, rise in research and development activities by key market players and increase in healthcare expenditure has further encouraged many key players to enter emerging markets, thus offering lucrative opportunities for the expansion of the antiemetics market. Also, the presence of raw material in the developing regions such as Asia and LAMEA, provides lucrative opportunities for the market players to invest in this region.
The global antiemetics market is segmented on the basis of drug type, application, distribution channel, and region. By drug type, the market is categorized into antihistamines, serotonin receptor antagonists, dopamine receptor antagonists, neurokinin receptor antagonists, anticholinergics, and others. Depending on application, it is segmented into chemotherapy, post-operative surgery, pregnancy and gastroenteritis, and others. On the basis distribution channel, it is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global Antiemetics market are Abbott Laboratories, Benuvia Therapeutics Inc., Cipla, Dr. Reddy’s Laboratories Ltd, Eisai Co. Ltd, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Pfizer In. and Teva Pharmaceuticals among others.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antiemetics market analysis from 2021 to 2031 to identify the prevailing antiemetics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the antiemetics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global antiemetics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Type
- Antihistamines
- Serotonin Receptor Antagonists
- Dopamine Receptor Antagonists
- Neurokinin Receptor Antagonists
- Anticholinergics
- Other Drug Types
By Application
- Chemotherapy
- Post Operative Surgery
- Pregnancy and Gatroenteritis
- Other Applications
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Region
- North America
- U. S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest Of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
Key Market Players
- GlaxoSmithKline Plc
- Sanofi
- Novartis AG
- Pfizer Inc
- Merck & Co. Inc
- Dr. Reddy’s Laboratories Ltd
- Cipla
- Johnson & Johnson
- Torrent Pharmaceuticals Ltd
- Acacia Pharma Group
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
CHAPTER 4: ANTIEMETICS MARKET, BY DRUG TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Antihistamines
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Serotonin Receptor Antagonists
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Dopamine Receptor Antagonists
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Neurokinin Receptor Antagonists
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Anticholinergics
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
4.7 Other Drug Types
4.7.1 Key market trends, growth factors and opportunities
4.7.2 Market size and forecast, by region
4.7.3 Market analysis by country
CHAPTER 5: ANTIEMETICS MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Chemotherapy
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Post Operative Surgery
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Pregnancy and Gatroenteritis
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Other Applications
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
CHAPTER 6: ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Retail Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Hospital Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online Pharmacies
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: ANTIEMETICS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Type
7.2.3 North America Market size and forecast, by Application
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U. S.
7.2.5.1.1 Market size and forecast, by Drug Type
7.2.5.1.2 Market size and forecast, by Application
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Drug Type
7.2.5.2.2 Market size and forecast, by Application
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Drug Type
7.2.5.3.2 Market size and forecast, by Application
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Type
7.3.3 Europe Market size and forecast, by Application
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Drug Type
7.3.5.1.2 Market size and forecast, by Application
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Drug Type
7.3.5.2.2 Market size and forecast, by Application
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Drug Type
7.3.5.3.2 Market size and forecast, by Application
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Drug Type
7.3.5.4.2 Market size and forecast, by Application
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Drug Type
7.3.5.5.2 Market size and forecast, by Application
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Drug Type
7.3.5.6.2 Market size and forecast, by Application
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Type
7.4.3 Asia-Pacific Market size and forecast, by Application
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 China
7.4.5.1.1 Market size and forecast, by Drug Type
7.4.5.1.2 Market size and forecast, by Application
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 Japan
7.4.5.2.1 Market size and forecast, by Drug Type
7.4.5.2.2 Market size and forecast, by Application
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Drug Type
7.4.5.3.2 Market size and forecast, by Application
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Drug Type
7.4.5.4.2 Market size and forecast, by Application
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Drug Type
7.4.5.5.2 Market size and forecast, by Application
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Drug Type
7.4.5.6.2 Market size and forecast, by Application
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Type
7.5.3 LAMEA Market size and forecast, by Application
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Drug Type
7.5.5.1.2 Market size and forecast, by Application
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Drug Type
7.5.5.2.2 Market size and forecast, by Application
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Drug Type
7.5.5.3.2 Market size and forecast, by Application
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Drug Type
7.5.5.4.2 Market size and forecast, by Application
7.5.5.4.3 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Players
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 GlaxoSmithKline Plc
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Sanofi
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Novartis AG
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Pfizer Inc
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Merck & Co. Inc
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Dr. Reddy’s Laboratories Ltd
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Cipla
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Johnson & Johnson
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Torrent Pharmaceuticals Ltd
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Acacia Pharma Group
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
Executive Summary
According to this report, titled, 'Antiemetics Market,' the antiemetics market was valued at $2.3 billion in 2021, and is estimated to reach $4.1 billion by 2031, growing at a CAGR of 6.1% from 2022 to 2031.Antiemetics Market is likely to experience a significant growth rate of 6.1% from 2022-2031 owing to increasing market demand from pharmaceutical sector - according to the analyst.
Antiemetics are the medications used in the prevention and treatment of the emesis. The antiemetic market is expected to expand due to the factors such as rise in prevalence of gastroenteritis and other gastric issues, high prevalence of cancer and subsequent rise in chemotherapies and rise in vertigo prevalence. Also, conditions such as food poisoning, pregnancy, motion sickness and others that cause nausea and vomiting will contribute to the growth of the market.
Key factors driving the growth of the antiemetics market include high prevalence of cancer and subsequent rise in chemotherapies, rise in prevalence of gastroenteritis and other gastric issue and rise in prevalence of vertigo. Furthermore, increase in demand for the antiemetics drugs for the treatment of conditions such as motion sickness, dizziness, pregnancy, emotional stress and food poisoning is propelling the growth of the market. For instance, according to Centers for Disease Control and Prevention (CDC), an estimated 1 in 6 Americans get sick due to food poisoning. Food poisoning is mainly associated with vomiting and nausea, which can be treated by using antiemetics medications. Thus, increase in incidences of food poisoning increases the demand for antiemetics drugs. This propels the market growth. Moreover, gradual prescription of oral antiemetic medications by the healthcare providers in developing regions due to low cost as compared injections, are expected to drive the market.
In addition, to meet the requirements of a wide costumers, manufacturers of antiemetic drug products have been concentrating on creating innovative and effective products, which propels the market growth. Moreover, antiemetic medications are easily available over the counter which makes its easily accessible for the population both in developed and developing countries. Also, availability of generic antiemetics medications which have comparatively low cost as compared to the branded drugs also boost the growth of the antiemetics market.
Furthermore, emerging economies of Asia-Pacific and LAMEA present lucrative opportunities for pharmaceutical market players. An emerging economy often experiences rapid economic growth which means that the emerging economy is increasing its production of goods and services. This might result from an increased population in the country or a growth in human capital. In addition, surge in healthcare industry, industrial development, and investments from developed countries in Asia-Pacific, is anticipated to offer lucrative opportunities for the growth of antiemetics market.
In addition, adequate number of investments by public and private sectors in R&D encourages use of new and advanced technologies for development of formulations in emerging countries. Thus, rise in adoption of these advanced emerging technologies for developments and manufacturing of antiemetics medications offers high quality products to the patients. This is anticipated to boost the market during the forecast period. In addition, rise in investments in healthcare sector by investors in developing regions creates lucrative opportunities for key players during the forecast period.
Antiemetics market was also driven due to the corona virus pandemic. Vaccination mainly reported nausea and vomiting conditions in huge population. Thus, there was a huge demand for antiemetics during the pandemic which boosted the growth of the market.
The global antiemetics market is segmented on the basis of drug type, application, distribution channel, and region. By drug type, the market is categorized into antihistamines, serotonin receptor antagonists, dopamine receptor antagonists, neurokinin receptor antagonists, anticholinergics, and others. Depending on application, it is segmented into chemotherapy, post-operative surgery, pregnancy and gastroenteritis, and others. On the basis distribution channel, it is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Some of the major companies that operate in the global antiemetics market are Abbott Laboratories, Benuvia Therapeutics Inc., Cipla, Dr. Reddy’s Laboratories Ltd, Eisai Co. Ltd, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Pfizer In. and Teva Pharmaceuticals among others.
Key Market Insights
- By drug type, the serotonin receptor antagonists segment was the highest revenue contributor to the market and is estimated to reach $91,293.60 million by 2031, with a CAGR of 7.1% and is estimated to be the fastest-growing segment during the forecast period.
- By application, the chemotherapy segment dominated the global market. However, the post operative surgery segment is expected to be the fastest-growing segment with a CAGR of 6.7% during the forecast period.
- Based on distribution channel, the retail pharmacies segment was the highest revenue contributor to the market, whereas the online pharmacies segment is anticipated to grow at the fastest rate during the forecast period.
- Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 7.8% during the forecast period
Companies Mentioned
- GlaxoSmithKline PLC
- Sanofi
- Novartis AG
- Pfizer Inc.
- Merck & Co. Inc.
- Dr. Reddy's Laboratories Ltd.
- Cipla
- Johnson & Johnson
- Torrent Pharmaceuticals Ltd.
- Acacia Pharma Group
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 260 |
| Published | November 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 2251.68 million |
| Forecasted Market Value ( USD | $ 4061.36 million |
| Compound Annual Growth Rate | 6.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
